JP2013508400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508400A5 JP2013508400A5 JP2012535373A JP2012535373A JP2013508400A5 JP 2013508400 A5 JP2013508400 A5 JP 2013508400A5 JP 2012535373 A JP2012535373 A JP 2012535373A JP 2012535373 A JP2012535373 A JP 2012535373A JP 2013508400 A5 JP2013508400 A5 JP 2013508400A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weeks
- days
- cancer
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25380409P | 2009-10-21 | 2009-10-21 | |
| US61/253,804 | 2009-10-21 | ||
| PCT/US2010/053579 WO2011050180A1 (en) | 2009-10-21 | 2010-10-21 | Novel dosing regimen and method of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508400A JP2013508400A (ja) | 2013-03-07 |
| JP2013508400A5 true JP2013508400A5 (https=) | 2013-12-05 |
Family
ID=43898626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535373A Withdrawn JP2013508400A (ja) | 2009-10-21 | 2010-10-21 | 新規な投与レジメンおよび治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110097345A1 (https=) |
| EP (1) | EP2490715A4 (https=) |
| JP (1) | JP2013508400A (https=) |
| KR (1) | KR20120094472A (https=) |
| CN (1) | CN102630165A (https=) |
| AU (1) | AU2010310577A1 (https=) |
| BR (1) | BR112012009250A2 (https=) |
| CA (1) | CA2775806A1 (https=) |
| IL (1) | IL219279A0 (https=) |
| IN (1) | IN2012DN02826A (https=) |
| MX (1) | MX2012004406A (https=) |
| RU (1) | RU2012120691A (https=) |
| WO (1) | WO2011050180A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| EP2526118A4 (en) * | 2010-01-21 | 2013-11-13 | Immunogen Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
| WO2014052876A1 (en) * | 2012-09-28 | 2014-04-03 | Immunogen Inc. | Methods for increasing efficacy of cd56- based therapy |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| CA2911499A1 (en) * | 2013-05-14 | 2014-11-20 | Immunogen, Inc. | Anti-folr1 immunoconjugate dosing regimens |
| IL298044B2 (en) * | 2013-10-08 | 2024-11-01 | Immunogen Inc | Dosing regimens of anti-FOLR1 immunoconjugate |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| IL303436A (en) * | 2016-08-10 | 2023-08-01 | Celgene Quanticel Res Inc | Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas |
| AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| SG11202012257VA (en) * | 2018-06-26 | 2021-01-28 | Immunogen Inc | Immunoconjugates targeting adam9 and methods of use thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| TW202210104A (zh) * | 2020-06-04 | 2022-03-16 | 瑞典商生物創新國際有限公司 | 皮下抗體調配物 |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| EP4709485A1 (en) * | 2023-05-10 | 2026-03-18 | Legend Biotech Ireland Limited | Chimeric antigen receptors and methods of use thereof |
| CN120053673A (zh) * | 2025-02-11 | 2025-05-30 | 暨南大学 | 纳米前药及其制备方法和用途 |
| CN120173115A (zh) * | 2025-05-20 | 2025-06-20 | 苏州欣协生物科技有限公司 | 一种抗人cd56蛋白工程抗体及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7303749B1 (en) * | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| AU775373B2 (en) * | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| IL159422A0 (en) * | 2001-09-20 | 2004-06-01 | Cornell Res Foundation Inc | Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| KR101424624B1 (ko) * | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
| CA2525987A1 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| ZA200708694B (en) * | 2005-04-15 | 2009-01-28 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors |
| EP3569245A1 (en) * | 2006-09-26 | 2019-11-20 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| WO2010008726A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen Inc. | Novel synergistic effects |
| EP2526118A4 (en) * | 2010-01-21 | 2013-11-13 | Immunogen Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER |
| AU2012240448A1 (en) * | 2011-04-01 | 2013-03-28 | Immunogen, Inc. | Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer |
-
2010
- 2010-10-21 WO PCT/US2010/053579 patent/WO2011050180A1/en not_active Ceased
- 2010-10-21 BR BR112012009250A patent/BR112012009250A2/pt not_active IP Right Cessation
- 2010-10-21 RU RU2012120691/15A patent/RU2012120691A/ru unknown
- 2010-10-21 MX MX2012004406A patent/MX2012004406A/es not_active Application Discontinuation
- 2010-10-21 AU AU2010310577A patent/AU2010310577A1/en not_active Abandoned
- 2010-10-21 CA CA2775806A patent/CA2775806A1/en not_active Abandoned
- 2010-10-21 US US12/909,697 patent/US20110097345A1/en not_active Abandoned
- 2010-10-21 CN CN2010800455971A patent/CN102630165A/zh active Pending
- 2010-10-21 KR KR1020127008847A patent/KR20120094472A/ko not_active Withdrawn
- 2010-10-21 JP JP2012535373A patent/JP2013508400A/ja not_active Withdrawn
- 2010-10-21 IN IN2826DEN2012 patent/IN2012DN02826A/en unknown
- 2010-10-21 EP EP10825683.5A patent/EP2490715A4/en not_active Withdrawn
-
2012
- 2012-04-19 IL IL219279A patent/IL219279A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508400A5 (https=) | ||
| Huang et al. | Recent advances in CAR-T cell engineering | |
| US20230115328A1 (en) | Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| RU2012120691A (ru) | Новый режим дозирования и способ лечения | |
| Tempest-Roe et al. | Local therapies for inflammatory eye disease in translation: past, present and future | |
| CN102711825A (zh) | 用于施用EpCAMxCD3双特异性抗体的给药方案 | |
| KR20180100539A (ko) | 치료용 조성물, 병용 및 적용과 관련된 사용방법 | |
| JP2009518441A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| van de Donk et al. | Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies | |
| TW202220654A (zh) | 用於治療癌症之組合 | |
| JP2014505056A5 (https=) | ||
| CN118593691A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| Flinn et al. | Recent advances in graft-versus-host disease | |
| CN113939503A (zh) | 激酶抑制剂的结晶盐形式 | |
| WO2019169015A1 (en) | Anti cd6 antibodies for treating severe asthma | |
| Sato et al. | Effectiveness of tacrolimus in a case of immune checkpoint inhibitor-induced hepatotoxicity that was refractory to steroids and mycophenolate mofetil | |
| WO2023077069A1 (en) | Anti-ctla-4 antibody dosing regimens | |
| AU2022340804A1 (en) | Compositions and methods for treating cancers | |
| WO2022109299A1 (en) | Anti-galectin-9 antibodies and therapeutic uses thereof | |
| US20240342195A1 (en) | Agent for combination use comprising t cell and/or b cell activity regulator | |
| Jain et al. | Anti-PD-1 antibodies as a therapeutic strategy in classical Hodgkin lymphoma | |
| Bengsch et al. | Success of immune checkpoint blockade therapies–mechanisms and implications for hepatology | |
| JP2014508809A5 (https=) |